B4GALT1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL12015070	0.66	4/20
SCHEMBL12361503	0.66	4/20
SCHEMBL14088636	0.66	4/20
SCHEMBL14414538	0.66	4/20
SCHEMBL14583153	0.66	4/20
SCHEMBL12108959	0.61	4/20
SCHEMBL13614408	0.61	4/20
SCHEMBL14017122	0.61	4/20
SCHEMBL14027760	0.55	4/20
SCHEMBL14654380	0.49	4/20
SCHEMBL15935830	0.49	4/20
SCHEMBL13614520	0.48	4/20
SCHEMBL14017350	0.48	4/20
SCHEMBL13614496	0.48	4/20
SCHEMBL14017312	0.48	4/20
SCHEMBL14628959	0.39	4/20
SCHEMBL14598992	0.38	4/20
SCHEMBL13614486	0.75	3/20
SCHEMBL13614499	0.75	3/20
SCHEMBL14017280	0.75	3/20

Clinical trials — most relevant to B4GALT1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Role of SGLT2i in Management of Moderate AS	PHASE2/PHASE3	UNKNOWN
Сlinical Trial of Efficacy and Safety of Prospekta in the Treatment of Post-COVID-19 Asthenia.	PHASE3	COMPLETED
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer	PHASE1/PHASE2	COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	PHASE1/PHASE2	RECRUITING
OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease	PHASE2	COMPLETED
Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease)	PHASE2	COMPLETED
Pilot Study of the Efficacy of Nicotinamide (Vitamin B3) in Leber's Hereditary Optic Neuropathy	PHASE1	NOT_YET_RECRUITING
Autologous Stem Cell Transplantation of Cells Engineered to Express Alpha-Galactosidase A in Patients With Fabry Disease	PHASE1	COMPLETED
Study to Compare a Dose of Telotristat Etiprate in Subjects With Renal Impairment With Matched Subjects With Normal Renal Function	PHASE1	COMPLETED
Investigate Safety, Tolerability, PK/PD of J2H-1702 in Healthy Females	PHASE1	COMPLETED
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease	nan	RECRUITING
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)	nan	WITHDRAWN
Beraprost Sodium and Arterial Stiffness in Patients With Type 2 Diabetic Nephropathy	nan	UNKNOWN
the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease	nan	RECRUITING
Secondary Lactose Intolerance Due to Chronic Norovirus Infection	nan	COMPLETED
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation	nan	COMPLETED
BMN 110 US Expanded Access Program	nan	APPROVED_FOR_MARKETING
Evaluation of Gastrointestinal Symptoms Following Chilean Native Beans Consumption	nan	UNKNOWN
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy	nan	UNKNOWN
The Natural History of Alpha-Mannosidosis	nan	COMPLETED
Inactive FSH in Galactosemia	nan	UNKNOWN
Fabry Disease in High-risk Patients With Left Ventricular Hypertrophy: Prevalence and Implementation of a Clinical Score	nan	ACTIVE_NOT_RECRUITING
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease	nan	COMPLETED
A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain	nan	COMPLETED
Intervention and Outcomes in Duarte Galactosemia	nan	COMPLETED
Biomarker for Mannosidosis Disease (BioMannosidosis)	nan	WITHDRAWN
Pregnancy Chances in Classic Galactosemia	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a B4GALT1 binder may also engage these)

Protein	Name	Similarity
P15535	—	1.000	P15535 →
Q80WN9	—	1.000	Q80WN9 →
Q9Z2Y2	—	1.000	Q9Z2Y2 →
P08037	—	1.000	P08037 →
A8Y1P7	—	0.999	A8Y1P7 →
Q9JMK0	—	0.998	Q9JMK0 →
O60909	—	0.997	O60909 →
Q80WN8	—	0.997	Q80WN8 →
A0A1S6M251	—	0.997	A0A1S6M251 →
Q5EA87	—	0.997	Q5EA87 →
O43286	—	0.997	O43286 →
Q91YY2	—	0.997	Q91YY2 →
Q6P768	—	0.996	Q6P768 →
O60512	—	0.996	O60512 →
Q66HH1	—	0.996	Q66HH1 →
Q9GUM2	—	0.995	Q9GUM2 →
Q80WN7	—	0.994	Q80WN7 →
Q5NVN3	—	0.993	Q5NVN3 →
Q9WVK5	—	0.992	Q9WVK5 →
Q3YL68	—	0.992	Q3YL68 →
Q9JJ04	—	0.991	Q9JJ04 →
Q9P2W7	—	0.991	Q9P2W7 →
Q7KN92	—	0.991	Q7KN92 →
Q9VAQ8	—	0.991	Q9VAQ8 →
Q8IXK2	—	0.991	Q8IXK2 →
O60513	—	0.990	O60513 →
Q9UBX8	—	0.990	Q9UBX8 →
Q5EA41	—	0.990	Q5EA41 →
O88419	—	0.989	O88419 →
Q6P6V1	—	0.989	Q6P6V1 →